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Abstract
Background: Osteosarcoma is characterized by a high malignant and metastatic potential. CCL5 (previously called RANTES)
was originally recognized as a product of activated T cells, and plays a crucial role in the migration and metastasis of human
cancer cells. It has been reported that the effect of CCL5 is mediated via CCR receptors. However, the effect of CCL5 on
migration activity and integrin expression in human osteosarcoma cells is mostly unknown.
Methodology/Principal Findings: Here we found that CCL5 increased the migration and expression of avb3 integrin in
human osteosarcoma cells. Stimulation of cells with CCL5 increased CCR5 but not CCR1 and CCR3 expression. CCR5 mAb,
inhibitor, and siRNA reduced the CCL5-enhanced the migration and integrin up-regulation of osteosarcoma cells.
Activations of MEK, ERK, and NF-kB pathways after CCL5 treatment were demonstrated, and CCL5-induced expression of
integrin and migration activity was inhibited by the specific inhibitor and mutant of MEK, ERK, and NF-kB cascades. In
addition, over-expression of CCL5 shRNA inhibited the migratory ability and integrin expression in osteosarcoma cells.
Conclusions/Significance: CCL5 and CCR5 interaction acts through MEK, ERK, which in turn activates NF-kB, resulting in the
activations of avb3 integrin and contributing the migration of human osteosarcoma cells.
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Introduction
Regulated upon Activation Normal T cell Expressed and
Secreted (RANTES, CCL5), was originally recognized as a
product of activated T cells [1]. Now widely established as an
inflammatory chemokine, CCL5 is known to mediate chemotactic
activity in T cells, monocytes, dendritic cells, natural killer cells,
eosinophils, and basophils [2,3,4]. CCL5 is associated with chronic
inflammatory diseases such as rheumatoid arthritis, inflammatory
bowel disease, and cancer [5,6]. An association between CCL5
expression and cancer has been reported in melanoma, lung,
prostate, and pancreatic cancers [7,8,9]. The most striking findings
thus far have been with breast cancer [7,8]. Several investigations
have reported that CCL5 was detected in samples from patients
with breast cancer and that expression levels correlated with
disease progression [7,8].
Osteosarcoma is a high-grade malignant bone neoplasm that
occurs primarily in children and adolescents. The principles of
treatment of osteosarcoma have undergone dramatic changes in
the past 20 years. Until recently, 5-year survival of 20% with
surgical treatment alone was considered acceptable. This outcome
suggested that 80% of the patients had pulmonary metastasis at
the time of presentation [10]. Hence, chemotherapy is usually
employed in an adjuvant situation to improve the prognosis and
long-term survival. Recurrence usually occurs as pulmonary
metastases or, less frequently, metastases to distant bones or as a
local recurrence [11,12,13]. Thus, a novel strategy that would
efficiently inhibit metastasis, especially to the lung, from the
primary osteosarcoma site is highly desirable.
Decades of scrutiny into the molecular bases of cancer have
largely focused on what causes oncogenic transformation and the
incipient emergence of tumors [14]. The invasion of tumor cells is
a complex, multistage process. To facilitate cell motility, invading
cells need to change the cell-cell adhesion properties, rearrange the
extracellular matrix (ECM) environment, suppress anoikis, and
reorganize their cytoskeletons [15]. Integrins are a family of
transmembrane adhesion receptors comprising 19 a and 8 b
subunits that interact noncovalently to form up to 24 different
heterodimeric receptors. The combination of different integrin
subunits on the cell surface allows cells to recognize and respond to
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collagen, and vitronectin [16]. Because integrins are the primary
receptors for cellular adhesion to ECM molecules, they act as
crucial transducers of bidirectional cell signaling, regulating cell
survival, differentiation, proliferation, migration, and tissue
remodeling [17]. Activation and elevated expression of integrin-
coupled signaling effectors have been implicated in the induction
of a wide variety of human cancers, including those of the breast,
colon, prostate, and ovaries [18]. In addition, integrin has also
been implicated in metastasis of lung, breast, bladder, and colon
cancers [19,20,21].
Previous studies have shown that CCL5 modulates cell
migration and invasion in human cancer cells [9,22,23].
Interaction of CCL5 with its specific receptor CCRs on the
surface of cancer cells has been reported to induce cancer invasion
[6,22,23]. However, the effect of CCL5 and CCR receptor on
integrins expression and migration activity in human osteosarco-
ma cells is mostly unknown. Here we found a phenomenon
whereby CCL5 and CCR5 interaction increased the migration
and expression of avb3 integrin in human osteosarcoma cells. In
addition, MAPK kinase (MEK), ERK, and NF-kB signaling
pathways were involved.
Materials and Methods
Materials
Protein A/G beads, anti-mouse and anti-rabbit IgG-conjugated
horseradish peroxidase, rabbit polyclonal antibodies specific for p-
MEK, MEK, p-ERK, ERK, p-p65, p65, CCR5 siRNA, control
siRNA, control shRNA plasmid, and CCL5 shRNA plasmid were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Mouse monoclonal antibody specific for avb3 integrin was
purchased from Chemicon (Temecula, CA, USA). U0126,
PD98059, TPCK, and PDTC were purchased from Calbiochem
(San Diego, CA, USA). Mouse monoclonal antibody specific for
CCR5 and Met-RANTES were purchased from R&D Systems
(Minneapolis, MN, USA). The recombinant human CCL5 was
purchased from PeproTech (Rocky Hill, NJ, USA). The MEK1
dominant-negative mutant was a gift from Dr. W.M. Fu (National
Taiwan University, Taipei, Taiwan). The ERK2 dominant-
negative mutant was a gift from Dr. M. Cobb (South-Western
Medical Center, Dallas, TX). The NF-kB luciferase plasmid was
purchased from Stratagene (La Jolla, CA, USA). pSV-b-galacto-
sidase vector and luciferase assay kit were purchased from
Promega (Madison, MA, USA). All other chemicals were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Cell culture
The human osteosarcoma cell lines (U2OS and MG63) were
purchased from the American Type Cell Culture Collection
(Manassas, VA, USA). The cells were maintained in RPMI-1640
medium which was supplemented with 20 mM HEPES and 10%
heat-inactivated FCS, 2 mM-glutamine, penicillin (100 U/ml) and
streptomycin (100 mg/ml) at 37uC with 5% CO2.
Migration and invasion assay
The migration assay was performed using Transwell (Costar,
NY; pore size, 8-mm) in 24-well dishes. For invasion assay, filters
were precoated with 25 ml Matrigel basement membrane matrix
(BD Biosciences, Bedford, MA) for 30 min. The following
procedures were the same for both migration and invasion assays
[24]. Before performing the migration assay, cells were pretreated
for 30 min with different concentrations of inhibitors, including
the PD98059, U0126, PDTC, TPCK, or vehicle control (0.1%
DMSO). Approximately 2610
4 cells in 100 ml of serum-free
RPMI-1640 medium were placed in the upper chamber, and
300 ml of the same medium containing CCL5 was placed in the
lower chamber. The plates were incubated for 24 h at 37uCi n5 %
CO2, then cells were fixed in methanol for 15 min and stained
with 0.05% crystal violet in PBS for 15 min. Cells on the upper
side of the filters were removed with cotton-tipped swabs, and the
filters were washed with PBS. Cells on the underside of the filters
were examined and counted under a microscope. Each clone was
plated in triplicate in each experiment, and each experiment was
repeated at least three times [25].
Western blot analysis
The cellular lysates were prepared as described previously
[26,27]. Proteins were resolved on SDS-PAGE and transferred to
Immobilon polyvinyldifluoride (PVDF) membranes. The blots
were blocked with 4% BSA for 1 h at room temperature and then
probed with rabbit anti-human antibodies against MEK, p-MEK,
ERK, p-ERK, or p-p65 (1:1000) for 1 h at room temperature.
After three washes, the blots were subsequently incubated with a
donkey anti-rabbit peroxidase-conjugated secondary antibody
(1:1000) for 1 h at room temperature. The blots were visualized
by enhanced chemiluminescence using Kodak X-OMAT LS film
(Eastman Kodak, Rochester, NY). Quantitative data were
obtained using a computing densitometer and ImageQuant
software (Molecular Dynamics, Sunnyvale, CA).
Flow cytometric analysis
Human osteosarcoma cells were plated in six-well dishes. The
cells were then washed with PBS and detached with trypsin at
37uC. Cells were fixed for 10 min in PBS containing 1%
paraformaldehyde. After being rinsed in PBS, the cells were
incubated with mouse anti-human antibody against integrin
(1:100) for 1 h at 4uC. Cells were then washed again and
incubated with fluorescein isothiocyanate-conjugated goat anti-
rabbit secondary IgG (1:100; Leinco Tec. Inc., St. Louis, MO,
USA) for 45 min and analyzed by flow cytometry using FACS
Calibur and CellQuest software (BD Biosciences, Lincolin, NE,
USA).
ERK kinase activity assay
ERK kinase activity was assessed by ERK Kinase Activity Assay
Kit according to manufacturer’s instructions (Sigma-Aldrich, St.
Louis, MO, USA). ERK activity kit is based on a solid-phase
ELISA that uses a specific synthetic peptide as a substrate for ERK
and a polyclonal antibody that recognized the phosphorylated
form of the substrate.
Transfection and reporter gene assay
Human osteosarcoma cells were co-transfected with 0.8 mg kB
driven luciferase plasmid, 0.4 mg b-galactosidase expression
vector. Cells were grown to 80% confluent in 12 well plates and
were transfected on the following day by Lipofectamine 2000
(LF2000; Invitrogen). DNA and LF2000 were premixed for
20 min and then applied to the cells. RPMI-1640 containing 20%
FCS was added 4 h later. After 24 h transfection, the cells were
then incubated with the indicated agents. After further 24 h’s
incubation, the media were removed, and cells were washed once
with cold PBS. To prepare lysates, 100 ml reporter lysis buffer
(Promega, Madison, WI) was added to each well, and cells were
scraped from dishes. The supernatant was collected after
centrifugation at 11,000 g for 2 min. Aliquots of cell lysates
(20 ml) containing equal amounts of protein (20–30 mg) were
CCL5 Promotes Migration of Osteosarcoma
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35101placed into wells of an opaque black 96-well microplate. An equal
volume of luciferase substrate was added to all samples, and
luminescence was measured in a microplate luminometer. The
value of luciferase activity was normalized to transfection
efficiency monitored by the co-transfected b-galactosidase expres-
sion vector.
Quantitative real time PCR
Total RNA was extracted from osteosarcoma cells by using a
TRIzol kit (MDBio Inc., Taipei, Taiwan). Two mg of total RNA
was reverse transcribed into cDNA by using oligo(dT) primer
[28,29]. The quantitative real time PCR (qPCR) analysis was
carried out using TaqmanH one-step PCR Master Mix (Applied
Biosystems, CA). Two ml of cDNA were added per 25-ml reaction
with sequence-specific primers and TaqmanH probes. Sequences
for all target gene primers and probes were purchased commer-
cially (GAPDH was used as internal control) (Applied Biosystems,
CA). qPCR assays were carried out in triplicate on an
StepOnePlus sequence detection system. The cycling conditions
were 10-min polymerase activation at 95uC followed by 40 cycles
at 95uC for 15 s and 60uC for 60 s. The threshold was set above
the non-template control background and within the linear phase
of target gene amplification to calculate the cycle number at which
the transcript was detected (denoted CT).
Establishment of stably transfected cells
CCL5 shRNA or control shRNA plasmids are transfected into
cancer cells with Lipofetamine 2000 transfection reagent. Twenty-
four hours after transfection, stable transfectants are selected in
puromycin (Life Technologies) at a concentration of 10 mg/mL.
Thereafter, the selection medium is replaced every 3 days. After 2
weeks of selection in puromycin, clones of resistant cells are
isolated.
Statistics
The values given are means 6 S.E.M. The significance of
difference between the experimental groups and controls was
assessed by Student’s t test. The difference is significant if the p
value is ,0.05.
Results
CCL5 and CCR5 interaction induced migration of
osteosarcoma cells
CCL5 has been reported to stimulate directional migration and
invasion of human cancer cells [23,30]. CCL5-trigered migration
in osteosarcoma cells was examined using the Transwell assay.
CCL5 directed human osteosarcoma cell migration (U2OS and
MG63 cells) (Fig. 1A). We also found that CCL5 increased
invasive ability of human osteosarcoma cells through Matrigel
basement membrane matrix (Fig. 1B). Interaction of CCL5 with
its specific receptor CCR on the surface of cancer cells has been
reported to induce cancer migration [7,22]. Stimulation of cells
with CCL5 increased the mRNA expression of CCR5 but not
CCR1 and CCR3 (Fig. 1C), suggesting that the amplification loop
strengthens the CCL5-CCR5-signaling pathway. Pretreatment of
cells with CCR5 mAb or CCR5 receptor inhibitor (Met-
RANTES) reduced CCL5-increaed cell migration (Fig. 1D). In
addition, transfection of cells with CCR5 siRNA also blocked
CCL5-induced cell migration activity (Fig. 1E). Therefore, CCL5
and CCR5 interaction is very important in migration activity of
osteosarcoma cells.
CCL5-directed osteosarcoma cell migration involves avb3
integrin up-regulation
Previous studies have shown significant expression of integrin in
human osteosarcoma cells [31]. We therefore, hypothesized that
integrin may be involved in CCL5-directed osteosarcoma cell
migration. qPCR analysis showed that CCL5 induced av and
avb3 but not a2, a5, b1, and b5 integrin expression (Fig. 2A). To
confirm this finding, expression of cell surface integrin in response
to CCL5 was analyzed by flow cytometry. Treatment of MG63
cells with CCL5 induced the cell surface expression of avb3
integrin dose-dependently (Fig. 2B). Pretreatment of cells for
30 min with anti-avb3 monoclonal antibody (mAb) (10 mg/ml)
markedly inhibited the CCL5-induced cell migration (Fig. 2C).
The cyclic RGD peptide (cyclo-RGDfV) has been reported to bind
avb3 at high affinity and block its function effectively at low
concentrations [32]. Treatment of cells with cyclic RGD, but not
cyclic RAD, inhibited the CCL5-induced migration of osteosar-
coma (Fig. 2C). Furthermore, pretreatment of cells with CCR5
mAb or Met-RANTES also blocked CCL5-increased avb3
integrin expression (Fig. 2D&E). These data suggest that CCL5-
induced cancer migration through avb3 integrin up-regulation.
MEK and ERK signaling pathways are involved in the
CCL5-mediated cell migration of osteosarcoma cells
MEK/ERK signaling pathway can be activated by a variety of
growth factors, such as insulin and growth factors [33]. We then
examined whether CCL5 stimulation also enhances the activation
of the MEK/ERK pathway. Stimulation of cells with CCL5
induced MEK phosphorylation (Fig. 3A). CCL5-induced the
migration of osteosarcoma cells were greatly reduced by treatment
with MEK inhibitors PD98059 and U0126 (Fig. 3B). The MEK
inhibitors PD98095 and U0126 also inhibited the CCL5-increased
avb3 integrin expression (Fig. 3C&D). Transfection of cells with
MEK1 reduced the CCL5-mediated cell migration and avb3
integrin expression (Fig. 3B–D). Next, we examined whether ERK
involved in CCL5-induced cell migration and integrin expression
in human osteosarcoma cells. Stimulation of cells with CCL5
enhanced ERK phosphorylation and kinase activity (Fig. 4A&B).
In addition, transfection of cells with ERK2 mutant reduced the
CCL5-mediated cell migration and avb3 integrin expression
(Fig. 4C–E). Furthermore, CCL5-induced ERK kinase activity
was markedly inhibited if cells were pretreated for 30 min with
CCR5 mAb or PD98059 (Fig. 4F). Taken together, these results
indicate that the CCR5, MEK, and ERK pathway is involved in
CCL5-induced migration activity and avb3 integrin up-regulation
in human osteosarcoma cells.
Involvement of NF-kB in CCL5-induced cell migration
and integrin expression
As previously mentioned, NF-kB activation is necessary for the
migration and invasion of human osteosarcoma cells [31]. To
examine whether NF-kB activation is involved in the signal
transduction pathway caused by CCL5 that leads to cell migration
and integrin expression, the NF-kB inhibitor pyrrolidine dithio-
carbamate (PDTC) was used. Fig. 5A–C show that PDTC
inhibited the enhancement of cell migration and avb3 integrin
expression induced by CCL5. Furthermore, pretreatment of
osteosarcoma cells with an IkB protease inhibitor [L-1-tosyla-
mido-2-phenylenylethyl chloromethyl ketone (TPCK)] antago-
nized the potentiating action of cell migration and avb3 integrin
expression (Fig. 5A–C). Previous studies showed that p65 Ser
536
phosphorylation increases NF-kB transactivation [34], and the
antibody specific against phosphorylated p65 Ser
536 was used to
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with CCL5 for various time intervals resulted in p65 Ser
536
phosphorylation (Fig. 5D). To directly determine NF-kB activation
after CCL5 treatment, osteosarcoma cells were transiently
transfected with kB-luciferase as an indicator of NF-kB activation.
As shown in Fig. 5E, CCL5 treatment of osteosarcoma cells for
24 h caused increase in kB-luciferase activity. In addition, the
CCL5-induced increase in kB-luciferase activity was also inhibited
by treatment with CCR5 mAb, Met-RANTES, PD98059, and
U0126 (Fig. 5E). Co-transfection with MEK and ERK mutant or
CCR5 siRNA also reduced CCL5-increased NF-kB luciferase
activity (Fig. 5F). Taken together, these data suggest that activation
of CCR5 receptor, MEK, and ERK are required for CCL5-
induced NF-kB activation in human osteosarcoma cells.
Figure 1. CCL5 and CCR5 interaction increased migration of human osteosarcoma cells. (A&B) MG63 or U20S cells were incubated with
various concentrations of CCL5, and in vitro migration and invasion activity measured with the Transwell after 24 h. (C) MG63 cells were incubated
with CCL5 (3 ng/ml) for 24 h, and the mRNA expression of CCR1, CCR3 and CCR5 was examined by qPCR. MG63 or U20S cells were pretreated for
30 min with CCR5 Ab, Met-RANTES (D) or transfected with CCR5 siRNA (E) for 24 h. Then they were followed by stimulation with CCL5, and in vitro
migration was measured with the Transwell after 24 h. Results of five independent experiments performed are expressed. Results are expressed as
the mean 6 S.E. *, p,0.05 compared with control; #,p ,0.05 compared with CCL5-treated group.
doi:10.1371/journal.pone.0035101.g001
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MG63 or U20S cells were incubated with CCL5 (3 ng/ml) for 24 h, and the mRNA levels of av, a2, a5, b1, b3o rb5 integrin was determined using
qPCR. (B) MG63 or U20S cells were incubated with CCL5 (0.3–3 ng/ml) for 24 h, and the cell surface expression of avb3 integrin was determined using
flow cytometry. (C) MG63 or U20S cells were pretreated with avb3 monoclonal antibody (10 mg/ml), cyclic RGD (100 nM), or cyclic RAD (100 nM) for
30 min followed by stimulation with CCL5. The in vitro migration activity measured after 24 h. (D&E) MG63 or U20S cells were pretreated for 30 min
with CCR5 Ab or Met-RANTES followed by stimulation with CCL5. The integrin expression was examined by qPCR and flow cytometry analysis. Results
of five independent experiments performed are expressed. Results are expressed as the mean 6 S.E. *, p,0.05 compared with control; #,p ,0.05
compared with CCL5-treated group.
doi:10.1371/journal.pone.0035101.g002
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clone
To further confirm the CCL5 mediated cell migration and
integrin expression in human osteosarcoma cells, the CCL5-
shRNA expression cells was established. The CCL5 expression
level in stable transfectants was compared using qPCR. The
expression of CCL5 was dramatically inhibited by CCL5-shRNA
orientation in MG63/CCL5-shRNA cells (Fig. 6B). We sought to
characterize the cellular growth rate of control cells and
transfectants, by performing the MTT assay 1–6 days after cell
seeding. No appreciable difference in cell growth ability was
evident among these cells (data not shown), suggesting that CCL5
does not have any mitogenic effects in human osteosarcoma cells.
Furthermore, the migratory ability of these transfectants was
analyzed using a Transwell migration assay. Knockdown of CCL5
expression inhibited the migratory ability by approximately 75%
in MG63 cells (Fig. 6A). In addition, knockdown CCL5 also
reduced av and b3 integrin mRNA expression in MG63 cells
(Fig. 6C&D). Therefore, knockdown CCL5 reduces cell migration
and avb3 integrin expression in human osteosarcoma cells.
Discussion
Osteosarcoma is a debilitating, though not always fatal, high-
grade malignant bone neoplasm that targets children and
adolescents. The chemotherapies are not fully effective, and as a
result, 20% of all patients die due to metastasis of osteosarcoma-
cells to the lungs [12]. Therefore, it is important to develop
effective adjuvant therapy for preventing osteosarcoma metastasis.
We found that CCL5 increased cell migration in human
osteosarcoma cell lines. One of the mechanisms underlying
CCL5 directed migration was transcriptional up-regulation of
avb3 integrin and activation of CCR5 receptor, MEK, ERK, and
NF-kB pathways. In previous study has been reported that CCL5
increased lung cancer migration through PI3K/Akt pathway [23].
Chuang et al., reported that PKCd signaling is mediated CCL5-
induced migration in oral cancer cells [22]. Pretreatment of cells
with PI3K (Ly294002), Akt (Akt inhibitor), or PKCd (Rottlerin)
inhibitor partially reduced CCL5-induced cell migration in
osteosarcoma cells (Figure S1). Therefore, PI3K, Akt, or PKCd
pathways partially involved in CCL5-enhanced cell migration in
osteosarcoma. In this study, the only 75% inhibitor of migration
after cells treated with MEK, ERK, or NF-kB inhibitor.
Combination of PI3K or PKCd inhibitor with MEK/ERK
inhibitor complete reduced CCL5-induced cell migration (Figure
S1). Therefore, the other signaling pathways (including PI3K, Akt,
and PKCd) are also partially involved in CCL5-induced cell
migration in osteosarcoma cells. On the other hand, we also found
that CCL5 promotes the invasion of osteosarcoma cells (Fig. 1B).
We therefore examines the matrix metalloproteinases (MMPs)
Figure 3. MEK is involved in CCL5-mediated migration in human osteosarcoma cells. (A) MG63 cells were incubated with CCL5 for
indicated time intervals, and p-MEK expression was determined by Western blotting. (B–D) MG63 or U20S cells were pretreated with PD98059 and
U0126 for 30 min or transfected with dominant negative (DN) mutant of MEK1 for 24 h followed by stimulation with CCL5. The in vitro migration and
integrin expression was examined by Transwell, qPCR, and flow cytometry analysis. Results of five independent experiments performed are
expressed. Results are expressed as the mean 6 S.E. *, p,0.05 compared with control; #,p ,0.05 compared with CCL5-treated group.
doi:10.1371/journal.pone.0035101.g003
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increased the MMP-2 mRNA expression but not others MMP
(Figure S2). Pretreatment of cells with CCR5 mAb, PD98059,
U0126, PDTC, or TPCK reduced CCL5-incrased MMP-2
expression (Figure S2). Therefore, the same signaling pathway
involved in CCL5-induced cell migration and MMP-2 expression.
It has been reported that CCL5 mediates its biological activities
through activation of G protein–coupled receptors, CCR1, CCR3,
or CCR5, and binds to glycosaminoglycans [35]. Stimulation of
MG63 cells with CCL5 increased the mRNA expression of CCR5
but not CCR1 and CCR3. Therefore, CCR5 is more important
than CCR1 and CCR3 in CCL5-mediated cell functions. In this
Figure 4. ERK is involved in CCL5-mediated migration in human osteosarcoma cells. (A) MG63 cells were incubated with CCL5 for
indicated time intervals, and p-ERK expression was determined by Western blotting. (B) MG63 cells were incubated with CCL5 for indicated time
intervals, and ERK kinase activity was examined by ERK kinase assay kit. (C–E) MG63 or U20S cells were transfected with dominant negative (DN)
mutant of ERK2 for 24 h followed by stimulation with CCL5. The in vitro migration and integrin expression was examined by Transwell, qPCR, and
flow cytometry analysis. Results of five independent experiments performed are expressed. Results are expressed as the mean 6 S.E. *, p,0.05
compared with control; #,p ,0.05 compared with CCL5-treated group.
doi:10.1371/journal.pone.0035101.g004
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regulated after CCL5 stimulation. In addition, CCR5 Ab, Met-
RANTES, or CCR5 siRNA also blocked CCL5-incrased avb3
integrin expression. Therefore, CCR5 is upstream receptor
involved in CCL5-increaed cell migration and integrin expression.
Whether other physical or functional connection between these
receptors is needs further examination.
Figure 5. CCL5 induces cell migration and avb3 integrin expression through NF-kB. (A–C) MG63 or U20S cells were pretreated for 30 min
with PDTC or TPCK followed by stimulation with CCL5. The in vitro migration and integrin expression was examined by Transwell, qPCR, and flow
cytometry analysis. (D) MG63 cells were incubated with CCL5 for indicated time intervals, and p-p65 expression was determined by Western blotting.
(E&F) MG63 cells were pretreated with CCR5 Ab, Met-RANTES, PD98059, and U0126 for 30 min or co-transfected with MEK1 and ERK2 mutant or CCR5
siRNA before exposure to CCL5. The NF-kB driven luciferase activity was measured, and the results were normalized to the b-galactosidase activity
and expressed as the mean 6 S.E. for three independent experiments performed in triplicate. Results of five independent experiments performed are
expressed. Results are expressed as the mean 6 S.E *, p,0.05 compared with control; #,p ,0.05 compared with CCL5-treated group.
doi:10.1371/journal.pone.0035101.g005
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and signaling molecules and are implicated in the regulation of a
number of cellular processes, including adhesion, signaling,
motility, survival, gene expression, growth, and differentiation
[36]. Here we found that CCL5 increased avb3 integrin
expression by using flow cytometry analysis, which plays an
important role during tumor metastasis. Furthermore, CCL5 also
increased the mRNA levels of av and b3 integrins. In the present
study, we used avb3 integrin antibody to determine the role of
avb3 integrin and found that it inhibited CCL5-induced cancer
migration, indicating the possible involvement of avb3 integrin in
CCL5-induced migration in osteosarcoma cells. This was further
confirmed by the result that the cyclic RGD inhibited the
enhancement of migration activity by CCL5, indicating the
involvement of avb3 integrin in CCL5-mediated induction of
cancer migration.
MEK/ERK pathway plays a critical role in CCL5/CCR5
signaling [37]. We found that PD98059 and U0126 (MEK
inhibitors) inhibited CCL5-induced migration. Stimulation of cells
with CCL5 increased phosphorylation of MEK and ERK. CCL5
also increased the ERK kinase activity. Transfection of cells with
MEK or ERK mutant blocked CCL5-mediated migration and
integrin expression. Furthermore, CCL5-induced ERK kinase
activity was antagonized by CCR5 mAb and PD98059, indicating
that the CCR5 receptor and MEK occur as the upstream
molecules involved in CCL5-induced activation of ERK.
A variety of growth factors stimulate cancer metastasis via
signal-transduction pathways that converge to activate NF-kB
complex of transcription factors [38]. The results of this study
show that NF-kB activation contributes to CCL5-induced avb3
integrin expression and migration in human osteosarcoma cells,
and that the inhibitors of the NF-kB-dependent signaling pathway,
including PDTC or TPCK inhibited CCL5-induced avb3 integrin
expression and cancer migration. Using transient transfection with
kB-luciferase as an indicator of NF-kB activity, we also found that
CCL5-induced an increase in NF-kB activity. p65 is phosphor-
ylated at Ser
536 by a variety of kinases through various signaling
pathways, and this enhances the p65 transactivation potential. The
results of this study showed that CCL5 increased the phosphor-
ylation of p65. On the other hand, CCR5 Ab, Met-RANTES,
PD98059, and U0126 reduced CCL5-mediated NF-kB promoter
activity. Our data indicated that CCR5, MEK, ERK, and NF-kB
pathways might play important role in the expression of avb3
integrin and cell migration of human osteosarcoma cells.
Due to the prognosis of patients with osteosarcoma distant
metastasis is generally considered as very poor. Thus, preventing
human osteosarcoma metastasis is an important issue nowadays.
Our study presents that CCL5 and CCR5 interaction increases
the expression of avb3 integrin via MEK, ERK, p65, and NF-kB-
dependent pathway and increasing migration of human osteosar-
coma cells. To the best of our knowledge, this study is first time to
attempt to examine the migratory activity of CCL5 in human
Figure 6. Knockdown of CCL5 inhibited the migratory ability in osteosarcoma cells. (A) The in vitro migration activity of MG63/control-
shRNA and MG63/CCL5-shRNA cells was measured with the Transwell. (B–D) The mRNA levels of CCL5, av and b3 integrin in MG63/control-shRNA
and MG63/CCL5-shRNA cells was examined by qPCR. Results are expressed as the mean 6 S.E.
doi:10.1371/journal.pone.0035101.g006
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show the expression of CCL5 in osteosarcoma and healthy
patients. Whether CCL5 acts through same pathways to induce
cell motility in clinic should be examined further. Furthermore,
the discovery of CCL5-mediated pathway helps us to understand
the mechanism of human osteosarcoma metastasis and may help
us to develop effective therapy in the future.
Supporting Information
Figure S1 PI3K, Akt, and PKCd pathways are partially
involved in CCL5-induced cell migration. MG63 cells were
incubated with Ly294002, Akt inhibitor, Rottlerin, PD98059 plus
Ly294002, or PD98058 plus Rottlerin for 30 min followed by
stimulation with CCL5. The in vitro migration activity measured
after 24 h. Results are expressed as the mean 6 S.E. *, p,0.05
compared with control; #,p ,0.05 compared with CCL5-treated
group.
(TIF)
Figure S2 CCR5, MEK, ERK, and NF-kB pathway is
involved in CCL5-induced MMP-2 expression. (A) MG63
cells were incubated with CCL5 for 24 h, and the mRNA levels of
MMPs was determined using qPCR. (B) MG63 cells were
pretreated with CCR5 mAb, PD98059, U0126, PDTC, or TPCK
for 30 min followed by stimulation with CCL5. The MMP-2
mRNA expression was determined using qPCR. Results are
expressed as the mean 6 S.E. *, p,0.05 compared with control;
#,p ,0.05 compared with CCL5-treated group.
(TIF)
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